CDMO News
UCB Invests $353M in Samsung Biologics for Drug Substance Manufacturing
UCB, the multinational biopharmaceutical company headquartered in Brussels, Belgium. and CDMO Samsung Biologics of South Korea have expanded their seven-year partnership with a new drug substance manufacturing deal worth 382 billion Korean won ($353 million). The partnership involves Samsung Biologics manufacturing several